+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Sino Biopharmaceutical Ltd (1177) - Financial and Strategic SWOT Analysis Review

  • ID: 4278590
  • SWOT Analysis
  • June 2022
  • 58 Pages
  • GlobalData
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

FEATURED COMPANIES

  • CanSino Biologics Inc
  • SSY Group Ltd
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Sino Biopharmaceutical Ltd (1177) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions
  • Corporate strategy - Analyst’s summarization of the company’s business strategy
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats
  • Company history - Progression of key events associated with the company
  • Major products and services - A list of major products, services and brands of the company
  • Key competitors - A list of key competitors to the company
  • Key employees - A list of the key executives of the company
  • Executive biographies - A brief summary of the executives’ employment history
  • Key operational heads - A list of personnel heading key departments/functions
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history

Highlights

Sino Biopharmaceutical Ltd (Sino Biopharma), a subsidiary of Charoen Pokphand Group, is a research-oriented pharmaceutical company that develops, manufactures, and markets medicines, biopharmaceuticals, and Chinese medicines. It offers medicines for the treatment of hepatitis, cardio-cerebral diseases, cancer, orthopedic conditions, infectious diseases, and respiratory and digestive diseases, among others. The company offers products in various dosage forms including large-volume injections, PVC-free soft bags for intravenous injections, small-volume injections, powdered medicines, granulated medicines, capsules, and tablets. It works in partnership with several domestic and foreign pharmaceutical companies to advance the development of its products. Sino Biopharma is headquartered in Beijing, China.

Sino Biopharmaceutical Ltd Key Recent Developments

Mar 31, 2022: Sino Biopharmaceutical announces annual results announcement for the year ended 31 December, 2021
Mar 28, 2022: Sino Biopharmaceutical: Methacholine chloride powder for solution, for inhalation obtained drug registration certificate
Mar 11, 2022: Sino Biopharmaceutical: Voluntary announcement entering into cooperative development agreement for fully human antibody drugs
Aug 31, 2021: Sino Biopharmaceutical: Interim results announcement for the six months ended 30 June, 2021
Aug 18, 2021: Sino Biopharmaceutical positive profit alert announcement

Key benefits of buying this profile include:


You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios

Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs

Note: Some sections may be missing if data is unavailable for the company

FEATURED COMPANIES

  • CanSino Biologics Inc
  • SSY Group Ltd

Section 1 - About the Company
  • Sino Biopharmaceutical Ltd - Key Facts
  • Sino Biopharmaceutical Ltd - Key Employees
  • Sino Biopharmaceutical Ltd - Key Employee Biographies
  • Sino Biopharmaceutical Ltd - Major Products and Services
  • Sino Biopharmaceutical Ltd - History
  • Sino Biopharmaceutical Ltd - Company Statement
  • Sino Biopharmaceutical Ltd - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries

Section 2 - Company Analysis
  • Company Overview
  • Sino Biopharmaceutical Ltd - Business Description
  • Product Category: Cardio-Cerebral Medicines
  • Performance
  • Product Category: Hepatitis Medicines
  • Overview
  • Performance
  • Product Category: Oncology Medicines
  • Overview
  • Performance
  • Product Category: Orthopedic Medicines
  • Overview
  • Performance
  • Product Category: Others
  • Overview
  • Performance
  • Product Category: Parenteral Nutritious Medicines
  • Performance
  • Product Category: Respiratory System Medicines
  • Overview
  • Performance
  • R&D Overview
  • Sino Biopharmaceutical Ltd - Corporate Strategy
  • Sino Biopharmaceutical Ltd - SWOT Analysis
  • SWOT Analysis - Overview
  • Sino Biopharmaceutical Ltd - Strengths
  • Sino Biopharmaceutical Ltd - Weaknesses
  • Sino Biopharmaceutical Ltd - Opportunities
  • Sino Biopharmaceutical Ltd - Threats
  • Sino Biopharmaceutical Ltd - Key Competitors

Section 3 - Company Financial Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts

Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Sino Biopharmaceutical Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
  • Sino Biopharmaceutical Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2016 to YTD 2022
  • Sino Biopharmaceutical Ltd, Recent Deals Summary

Section 5 - Company’s Recent Developments
  • Mar 31, 2022: Sino Biopharmaceutical announces annual results announcement for the year ended 31 December, 2021
  • Mar 28, 2022: Sino Biopharmaceutical: Methacholine chloride powder for solution, for inhalation obtained drug registration certificate
  • Mar 11, 2022: Sino Biopharmaceutical: Voluntary announcement entering into cooperative development agreement for fully human antibody drugs
  • Aug 31, 2021: Sino Biopharmaceutical: Interim results announcement for the six months ended 30 June, 2021
  • Aug 18, 2021: Sino Biopharmaceutical positive profit alert announcement
  • May 24, 2021: Sino Biopharmaceutical 2021 first quarterly profit attributable to owners of the parent soars 118.5% to RMB1.91 Billion
  • May 10, 2021: Sino Biopharmaceutical announces appointment of Chief Medical Officer
  • Feb 26, 2021: Sino Biopharmaceutical announces change of address of share registrar and transfer agent in the Cayman Islands

Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer

List of Tables
  • Sino Biopharmaceutical Ltd, Key Facts
  • Sino Biopharmaceutical Ltd, Key Employees
  • Sino Biopharmaceutical Ltd, Key Employee Biographies
  • Sino Biopharmaceutical Ltd, Major Products and Services
  • Sino Biopharmaceutical Ltd, History
  • Sino Biopharmaceutical Ltd, Other Locations
  • Sino Biopharmaceutical Ltd, Subsidiaries
  • Sino Biopharmaceutical Ltd, Key Competitors
  • Sino Biopharmaceutical Ltd, Annual Ratios
  • Sino Biopharmaceutical Ltd, Interim Ratios
  • Sino Biopharmaceutical Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
  • Sino Biopharmaceutical Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2016 to YTD 2022
  • Sino Biopharmaceutical Ltd, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios

List of Figures
  • Sino Biopharmaceutical Ltd, Performance Chart (2017 - 2021)
  • Sino Biopharmaceutical Ltd, Ratio Charts
  • Sino Biopharmaceutical Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
  • Sino Biopharmaceutical Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2016 to YTD 2022

Loading
LOADING...

A selection of companies mentioned in this report includes:

  • Tibet Rhodiola Pharmaceutical Holding Co Ltd
  • The United Laboratories International Holdings Ltd
  • SSY Group Ltd
  • Shanghai Fosun Pharmaceutical (Group) Co Ltd
  • Jiangsu Hengrui Medicine Co Ltd
  • Guizhou YiBai Pharmaceutical Co Ltd
  • Dawnrays Pharmaceutical (Holdings) Ltd
  • China Resources Pharmaceutical Group Ltd
  • CanSino Biologics Inc